Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL20720787

COc1cc2c(Cl)c3ccccc3nc2cc1OCCCN(C)C.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.44
▸ EHMT2 Q96KQ7 2/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ RCOR1 Q9UKL0 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ AXL P30530 1/20 0.41
▸ TOP2A P11388 1/20 0.41
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ RET P07949 1/20 0.41
▸ KIF5B P33176 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ PDPK1 O15530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260709 0.91 EGFR (0.49) EGFREHMT2KDM1ARCOR1CYP1A2
Trifluoroacetic Acid SCHEMBL19260723 0.91 EGFR (0.46) EGFRCYP1A2CYP2D6BCHEACHE
Trifluoroacetic Acid SCHEMBL19260557 0.87 EGFR (0.44) EGFREHMT2KDM1ARCOR1AXL
SCHEMBL20734756 0.81 EGFR (0.50) EGFREHMT2KDM1ARCOR1BCHE
Trifluoroacetic Acid SCHEMBL19260559 0.78 KDM4E (0.45) EGFREHMT2CYP1A2CYP2D6BCHE
SCHEMBL19260524 0.77 EGFR (0.50) EGFREHMT2KDM1ARCOR1TOP2A
SCHEMBL11809733 0.76 MAOA (0.60) EHMT2KDM4ETDP1PDPK1
SCHEMBL19260666 0.73 TLR7 (0.59) EHMT2
SCHEMBL19260694 0.72 SPIN1 (0.58) EHMT2
SCHEMBL19272512 0.71 EGFR (0.58) EGFRAXLRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EGFR 4848/4885EHMT2 2/4885KDM1A 15/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EGFR 4848/4885EHMT2 2/4885KDM1A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback